Psoriatic Arthritis PBMC
About: Psoriatic Arthritis PBMC samples are collected from clinically confirmed psoriatic arthritis donors and cryopreserved. These PBMCs are ideal for genetic and epigeneitc changes relevant to psoriatic arthritis pathogenesis.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 75204 | Psoriatic Arthritis | 5M | Hispanic/Latino | 57 | Male | 6 | $765.00 | |||
| 77618 | Psoriatic Arthritis | 5M | Hispanic/Latino | 63 | Female |
JAK inhibitor
|
27 | $765.00 | ||
| 76297 | Psoriatic Arthritis | 5M | Hispanic/Latino | 58 | Male |
Methotrexate
|
6 | $765.00 | ||
| 76300 | Psoriatic Arthritis | 5M | Hispanic/Latino | 73 | Female | 28 | $765.00 | |||
| 76294 | Psoriatic Arthritis | 5M | Hispanic/Latino | 78 | Female |
Methotrexate
|
1 | $765.00 | ||
| 76303 | Psoriatic Arthritis | 5M | Hispanic/Latino | 73 | Male | 10 | $765.00 | |||
| 69582 | Psoriatic Arthritis | 10M | Caucasian | 51 | Female | 3 | $765.00 | |||
| 76299 | Psoriatic Arthritis | 5M | Hispanic/Latino | 74 | Female |
Methotrexate
|
2 | $765.00 | ||
| 74700 | Psoriatic Arthritis | 10M | Caucasian | 69 | Female | United States (US) |
Otezla 30 mg BID Bupropion 150 mg QD Fluoxetine 120 mg QD Atorvastatin 5 mg QD
|
9 | $765.00 | |
| 74572 | Psoriatic Arthritis | 10M | Caucasian | 65 | Male | United States (US) |
Lipitor 10 mg QD Methotrexate 15 mg QW Folic Acid 1 mg QD Wegovy 1.7 mg QW
|
17 | $765.00 |
High-Quality Psoriatic Arthritis PBMC for Research
Psoriatic Arthritis Human PBMC products are sourced from donors clinically diagnosed with psoriatic arthritis and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune cell subsets, cytokine response, and gene expression signatures related to disease pathogenesis.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed psoriatic arthritis donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified psoriatic arthritis diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional Psoriatic Arthritis-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in psoriatic arthritis pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Psoriatic Arthritis PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.
1 Answer
YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.
1 Answer
Self-reported infectious disease testing is always available and some of our products have additional testing.
1 Answer
HLA-typing is available for some of our PBMC products.
1 Answer
YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.
1 Answer
Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.